Heterogeneous adaptation of cysteine reactivity to a covalent oncometabolite

J Biol Chem. 2020 Sep 25;295(39):13410-13418. doi: 10.1074/jbc.AC120.014993. Epub 2020 Aug 19.

Abstract

An important context in which metabolism influences tumorigenesis is the genetic cancer syndrome hereditary leiomyomatosis and renal cell carcinoma (HLRCC), a disease in which mutation of the tricarboxylic acid cycle enzyme fumarate hydratase (FH) causes hyperaccumulation of fumarate. This electrophilic oncometabolite can alter gene activity at the level of transcription, via reversible inhibition of epigenetic dioxygenases, as well as posttranslationally, via covalent modification of cysteine residues. To better understand the potential for metabolites to influence posttranslational modifications important to tumorigenesis and cancer cell growth, here we report a chemoproteomic analysis of a kidney-derived HLRCC cell line. Using a general reactivity probe, we generated a data set of proteomic cysteine residues sensitive to the reduction in fumarate levels caused by genetic reintroduction of active FH into HLRCC cell lines. This revealed a broad up-regulation of cysteine reactivity upon FH rescue, which evidence suggests is caused by an approximately equal proportion of transcriptional and posttranslational modification-mediated regulation. Gene ontology analysis highlighted several new targets and pathways potentially modulated by FH mutation. Comparison of the new data set with prior studies highlights considerable heterogeneity in the adaptive response of cysteine-containing proteins in different models of HLRCC. This is consistent with emerging studies indicating the existence of cell- and tissue-specific cysteine-omes, further emphasizing the need for characterization of diverse models. Our analysis provides a resource for understanding the proteomic adaptation to fumarate accumulation and a foundation for future efforts to exploit this knowledge for cancer therapy.

Keywords: TCA cycle; chemical biology; inborn error of metabolism; metabolism; mitochondria; posttranslational modification (PTM); proteomics; redox signaling; tricarboxylic acid cycle (TCA cycle) (Krebs cycle).

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Cysteine / genetics
  • Cysteine / metabolism*
  • Fumarate Hydratase / genetics
  • Fumarate Hydratase / metabolism*
  • Fumarates / metabolism*
  • Humans
  • Kidney Neoplasms / genetics
  • Kidney Neoplasms / metabolism*
  • Kidney Neoplasms / pathology
  • Leiomyomatosis / genetics
  • Leiomyomatosis / metabolism*
  • Leiomyomatosis / pathology
  • Neoplastic Syndromes, Hereditary / genetics
  • Neoplastic Syndromes, Hereditary / metabolism*
  • Neoplastic Syndromes, Hereditary / pathology
  • Skin Neoplasms / genetics
  • Skin Neoplasms / metabolism*
  • Skin Neoplasms / pathology
  • Uterine Neoplasms / genetics
  • Uterine Neoplasms / metabolism*
  • Uterine Neoplasms / pathology

Substances

  • Fumarates
  • Fumarate Hydratase
  • Cysteine

Supplementary concepts

  • Hereditary leiomyomatosis and renal cell cancer